A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Tew, WP; Sill, M; McMeekin, DS; Secord, AA; Bonebrake, AJ; Schilder, J; Stuckey, A; Rice, L; Tewari, KS; Aghajanian, C

Published Date

  • May 20, 2014

Published In

Volume / Issue

  • 32 / 15_suppl

Start / End Page

  • 5546 - 5546

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2014.32.15_suppl.5546